ArticleWorld journal of microbiology & biotechnology2018
Hyporientalin A, an anti-Candida peptaibol from a marine Trichoderma orientale.
Article in World journal of microbiology & biotechnology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Activity of Secondary Metabolites from Marine-DerivedInternational journal of molecular sciences · 2026Article
- A Journey into the Blue: Current Knowledge and Emerging Insights into Marine-Derived Peptaibols.Marine drugs · 2025Review
- Chromatographic and mass spectroscopic guided discovery ofEngineering microbiology · 2024Review
- Marine-Derived Metabolites Act as Promising Antifungal Agents.Marine drugs · 2024Review
- Chemistry and biology of marine-derived Trichoderma metabolites.Natural products and bioprospecting · 2024Review
- Exploring the frontiers of therapeutic breadth of antifungal peptides: A new avenue in antifungal drugs.Journal of industrial microbiology & biotechnology · 2024Review
- The Importance of Microorganisms for Sustainable Agriculture-A Review.Metabolites · 2022Review
- Peptaibol Production and Characterization fromJournal of fungi (Basel, Switzerland) · 2022Article
- Peptaibols: Diversity, bioactivity, and biosynthesis.Engineering microbiology · 2022Review
- Essential Oils as a Good Weapon against Drug-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Rare Glutamic Acid Methyl Ester Peptaibols fromInternational journal of molecular sciences · 2021Article
- Antimicrobial Peptides: Novel Source and Biological Function With a Special Focus on Entomopathogenic Nematode/Bacterium Symbiotic Complex.Frontiers in microbiology · 2021Review
- Review
- Antifungal compounds with anticancer potential from Trichoderma sp. P8BDA1F1, an endophytic fungus from Begonia venosa.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020Article
- 14-Residue peptaibol velutibol A fromRSC advances · 2020Article
- High Production of Chitinolytic Activity in Halophilic Conditions by a New Marine Strain ofMolecules (Basel, Switzerland) · 2019Article
- Structural Diversity and Bioactivities of Peptaibol Compounds From the Longibrachiatum Clade of the Filamentous Fungal GenusFrontiers in microbiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A Trichoderma orientale strain LSBA1 was isolated from the Mediterranean marine sponge Cymbaxinella damicornis. The crude extract of T. orientale mycelium showed inhibitory activity against growth of Gram-positive and Gram-negative bacteria as well as clinical isolates of Candida albicans. Purification of the anti-Candida component was performed using a combination of open silica gel-60 column and reverse phase high performance liquid chromatography. The active compound called hyporientalin A has been identified as a peptaibol analogue of longibrachin-A-II using mass spectrometry. It exhibited fungicidal activity against clinical isolates of C. albicans with minimal inhibitory concentrations (MICs) ranging from 2.49 to 19.66 µM, comparable to that of the antifungal agent amphotericin B. Our data support the use of hyporientalin A as a promising new and efficient antifungal drug in the treatment of candidiasis while controlling toxicity.
Indexed as
Identifiers
29922855What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.